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ABSTRACT
Aim: To determine drug prescription and proportion of off-label dispensing in the
Swedish paediatric outpatient population.
Methods: All dispensed outpatient prescriptions to children aged 0 < 18 years as
well as the proportion of off-label drug use during 2007 were analysed using data from the
Swedish Prescribed Drug Register.
Results: In total, 2.19 million drug prescriptions of 898 different drug substances
were dispensed to paediatric patients, and of those substances, 64% had been dispensed
off-label at least once. The overall off-label rate of all prescriptions was 13.5%, among
which topical drugs as well as sex hormones were the most commonly prescribed off-label
drugs. More than half of all children in Sweden had received at least one prescribed drug in
2007.
Conclusions: There is a high prescribing of medicines to children in outpatient care
in Sweden with a considerable amount of off-label prescriptions. Topically administered
drugs, sex hormones, antidepressants, hypnotics, cardiovascular drugs and nonsteroidal
anti-inﬂammatory drugs were commonly prescribed off-label.
INTRODUCTION
Until recently, clinical trials in children were often regarded
as unethical. As a consequence, the majority of drugs pre-
scribed to children have not been studied in the paediatric
population. Hence, off-label prescribing is frequent in pae-
diatric routine care (1–9). As children’s growth and devel-
opment might lead to different efﬁcacy and⁄or safety
patterns compared to the adult population, the need for
studies in children is apparent.
A new legislation was introduced in 2006 to improve the
availability of safe and effective medicines for children in
Europe (10). According to the new legislation, the develop-
ment and accessibility of effective and safe medicinal prod-
ucts for paediatric patients should be facilitated by
identifying therapeutic areas in need of further research. For
this purpose, an inventory of current prescribing patterns to
children was requested from all EU Member States.
The objectives of this study were to investigate the drug
prescriptions in the Swedish paediatric outpatient popula-
tion and to analyse the proportion of off-label drug use.
METHODS
This is a nationwide study that includes all drug prescrip-
tions to children aged 0 < 18 years in Sweden during 2007.
Data were received as dispensed drug prescriptions at phar-
macies from the Swedish Prescribed Drug Register (SPDR)
hosted by the Centre of Epidemiology at the National Board
of Health and Welfare. The data set included 2.19 million
drug prescriptions of a total of 898 different drug substances
that had been dispensed to 968 465 paediatric patients
between 0 < 18 years. Of the 898 different substances, 386
were dispensed more than 100 times and those comprised
99.6% of the overall number of dispensations for children in
the SPDR and were included in the off-label analysis. Avail-
able information comprised product identiﬁcation, patient’s
date of birth and date of purchase. There was no informa-
tion with regard to dose or indication available in the SPDR
at the time of data collection. The drugs were categorized
according to the Anatomical Therapeutic Chemical (ATC)
classiﬁcation on the ﬁfth level and analysed regarding num-
ber of dispensed drug prescriptions (11).
Key notes
• This study indicates that a high proportion of Swedish
children are prescribed drugs in out-patient care and that
there is a considerable off-label drug prescribing. To
improve effective and safe use of drugs in children, more
paediatric research is needed, in particular for topically
administered drugs, cardiovascular drugs, antidepres-
sants, hypnotics and several NSAIDs.
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Distribution of dispensed drug prescriptions was divided
into six different age groups: 0 < 1, 1 < 2, 2 < 6, 6 < 12,
12 < 16 and 16 < 18 years. This age classiﬁcation was based
on the patient’s age at the time of drug prescribing.
Off-label classiﬁcation
The licence status of each drug was determined according
to the Summary of Product Characteristics (SmPC) (13,14).
In particular, information in sections 4.1, 4.2, 4.3 and 4.4,
concerning indications, posology, contraindications and
warnings and precautions, was used. Secondary reference
source for assessing licensed status was the published book-
let containing details about pharmacy prepared drugs for
children (15).
A dispensed drug prescription was regarded as off-label if
it was given outside the terms of the drug labelling, based on
four different categories:
1 A drug substance dispensed outside the age-limit in the
SmPC
2 A substance that lacked paediatric information in the
SmPC
3 A substance for which the SmPC stated that paediatric
clinical studies had not been performed
4 A substance that was explicitly not recommended or
contraindicated in children
Moreover, all unauthorized substances were coded as off-
label. Also, all pharmacy prepared drugs were coded as
off-label unless they were mentioned in the second refer-
ence source (15).
For practical reasons, the off-label classiﬁcation was
based on substance instead of the speciﬁc dispensed medici-
nal product. Therefore, it was necessary to make an assump-
tion that the product dispensed represented the widest on-
label age interval for that substance.
One substance could be classiﬁed off-label in more than
one of the four categories. For seven substances, an age-
limit could not be identiﬁed, and therefore, they were
excluded from further analysis.
RESULTS
Half (51%) of all children in Sweden had received at least
one prescribed drug during 2007 with a considerably higher
rate among children below age two (Table 1). The most
commonly prescribed drugs were drugs for the respiratory
tract (ATC-code R) and antibiotics (ATC-code J; Table 2).
Two hundred and forty-seven (64%) of the 386 sub-
stances included in the off-label analysis had been pre-
scribed off-label at least once, resulting in 295 000 off-label
drug prescriptions, constituting 13.5% of all dispensed pre-
scriptions to children. Pharmacy prepared drugs or unau-
thorized drugs accounted for 1.6% of all dispensed drugs.
In total, 512 substances were excluded from analysis as
they had been prescribed <100 times during 2007. This scat-
tered group constituted around 0.4% of all dispensations. A
preliminary analysis of those 512 excluded substances
Table 1 Total paediatric population 2007; number of unique individuals with prescriptions; percentage of all children with at least one prescribed drug; number of dispensed
prescriptions; dispensed prescriptions per patient, all by age groups
Age groups
(years)
Total
population N
Number of unique
individuals N
Percentage with
prescribed drug %
Number of dispensed
prescriptions N
Dispensed
prescriptions⁄patient
0 < 1 92 064 66 203 72 145 878 2.20
1 < 2 107 351 79 003 74 207 718 2.63
2 < 6 406 797 235 629 58 537 537 2.28
6 < 12 570 620 243 690 43 502 982 2.06
12 < 16 472 522 200 216 42 445 145 2.22
16 < 18 262 063 143 724 55 358 053 2.49
All ages 1 911 417 968 465 51 2 197 313 2.27
Table 2 Total number of dispensed substances within each anatomical therapeutic
chemical (ATC)-group and the percentage of dispensed drug prescriptions classiﬁed as
off-label
ATC- codes
Dispensations
N
All off-label
categories %
All 2 177 859 13.5
A. Alimentary tract & metabolism 93 745 11.1
B. Blood & blood forming organs 12 314 9.3
C. Cardiovascular system 14 654 18.3
D. Dermatologicals 196 333 29.5
G. Genitourinary system & sex hormones 95 241 97.3
H. Systemic hormonal preparations
excluding sex hormones
and insulins
49 685 1.0
J. Anti-infectives for systemic use 703 177 0.1
L. Antineoplastic & immune-modulating
agents
1326 0.8
M. Musculo-skeletal system 44 360 9.6
N. Nervous system 94 265 12.8
P. Antiparasitic products, insecticides
& repellents
19 243 0.3
R. Respiratory system 678 823 3.1
S. Sensory organs 173 436 52.4
V. Various 1257 0
Olsson et al. Outpatient paediatric off-label drug use
ª2011 The Author(s)/Acta Pædiatrica ª2011 Foundation Acta Pædiatrica 2011 100, pp. 1272–1275 1273showed that at least 150 of them were assessed as on-label
according to the criteria for this study.
The distribution of dispensed substances and the propor-
tion of off-label classiﬁcation by ATC code are presented in
Table 2. Drugs for infectious and respiratory tract diseases
were the most commonly dispensed substances, but had a
low off-label proportion. The highest off-label proportion
was found among drugs for topical use (for example topical
antifungals, fusidic acid, steroids and isotretinoin) and for
sex hormones (mainly hormonal contraceptives). Other
areas with a clinically important proportion of off-label drug
use were found among cardiovascular and psychiatric
(antidepressants, hypnotics, e.g. melatonin) drugs as well as
among drugs for the musculoskeletal system (mainly non-
steroidal anti-inﬂammatory drugs - NSAIDs).
The most common reason for off-label classiﬁcation in
general was a lack of paediatric information in the SmPC as
shown in Table 3. For example, with regard to cardiovascu-
lar drugs as well as to sex hormones, there was sparse or
nearly complete absence of paediatric information in the
SmPC, resulting in off-label classiﬁcation. In contrast, dis-
pensed drugs for the musculoskeletal system and psychiatric
drugs were mainly classiﬁed as off-label because of age or
stated lack of paediatric studies, or the drug was explicitly
not recommended or contraindicated in children.
DISCUSSION
In accordance with previous studies, high paediatric use of
antibiotics and of drugs for the respiratory tract was found,
mostly considered to be on-label with regard to age and
product information (5,8,16).
In a US population-based study, around 56% of chil-
dren <12 had used at least one medicinal product during
the week preceding the study (17). Whether our ﬁnding
that more than 70% of young children had been pre-
scribed a medicine in 2007 is in accordance with the US
ﬁnding is not possible to assess because of different
methodology.
The overall off-label rate of 13.5% found in this study was
slightly lower compared to a previous Swedish study in pae-
diatric outpatients in the Stockholm area, reporting an off-
label rate of 20.7% (4). This difference can be explained by
fewer off-label categories and analysis of substances instead
of medicinal products in the present study (4). Still, the
magnitude of off-label prescription is similar to that
reported in other studies (4,6,8).
The off-label proportion may have been underestimated
as the present study was restricted to the most commonly
dispensed drugs, although they represented more than 99%
of all dispensed drugs. The excluded drugs probably com-
prised drugs dispensed for children with rare diseases. It is
likely that several of those drugs had been prescribed off-
label. However, even if all those rarely prescribed drugs had
been classiﬁed as off-label, the off-label rate in the study
would not have changed much. The lack of possibility to
assess additional off-label categories such as dose and indi-
cation could also have resulted in an underestimation of the
off-label proportion.
As data were retrieved from SPDR at the ﬁfth ATC level,
no off-label analysis could be performed regarding the
formulation of the medicinal product, which also could
have contributed to an underestimation of the off-label
proportion.
Topically used drugs and sex hormones were associ-
ated with a high off-label proportion as also shown else-
where (8). However, sex hormones, mostly hormonal
contraceptives, are perhaps not the most important in
need of further paediatric research, because long clinical
experience does not suggest different efﬁcacy in the pae-
diatric population. However, there is still a need for
long-term safety follow-up. Topically used drugs, antide-
pressant drugs, hypnotics, cardiovascular drugs and dif-
ferent NSAIDs are considered in greater need of
paediatric clinical studies as they represent important
therapeutic areas in all paediatric age groups with very
different dose requirement as also suggested by other
investigators (8). Antidepressive agents have been high-
lighted in adolescents as drugs with a different adverse
drug reaction pattern compared to that seen in adults,
supporting the need for more paediatric clinical research
both on drug efﬁcacy and on safety (18,19).
As the present study, other studies on outpatient paediat-
ric drug use have demonstrated that the most common rea-
son for off-label classiﬁcation is complete lack of paediatric
information in the SmPC (4,20). A similar ﬁnding was also
reported in a recent prospective hospital-based study in
Sweden (1).
Table 3 Distribution of reasons for off-label classiﬁcation of all dispensed drugs clas-
siﬁed as off-label
ATC-code Off-label N
Age (i),
Lack of paediatric
clinical studies (iii),
Not recommended⁄
contraindicated in
children (iv)
Absence of
paediatric
information (ii)
Unauthorized
drugs and
pharmacy
prepared drugs
All 294 627 18.8 74.5 6.7
A 10 452 29.9 69.8 0.3
B 1145 43.2 56.8 0
C 2687 0 100 0
D 57 915 19.2 53.2 27.6
G 92 693 9.0 91.0 0
H 501 0 100 0
J 898 100 0 0
L 11 100 0 0
M 4274 97.5 2.5 0
N 12 043 76.4 20.5 3.1
P 63 100 0 0
R 21 137 72.0 15.1 12.9
S 90 808 3.0 96.5 0.5
V0 0 0 0
ATC, anatomical therapeutic chemical.
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There is a high prescribing of medicines to children in out-
patient care in Sweden. This population-based register
study indicates, in congruence with similar studies, that
there is a considerable off-label drug prescribing to children
in outpatient care in Sweden. The study identiﬁed some
important areas, such as topically administered drugs, sex
hormones, cardiovascular drugs, antidepressants, hypnotics
and several NSAIDs, where there appears to be a need for
more paediatric research to improve safe and effective use
of drugs in children.
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